# Also in the Article

REV-ERB agonist
This protocol is extracted from research article:
A mathematical model of circadian rhythms and dopamine
Theor Biol Med Model, Feb 17, 2021;

Procedure

Experiments using a synthetic REV-ERB agonist suggest that the agonist may induce phase shifts in major clock protein rhythms under 12hr light 12hr dark conditions [11]. We introduce another variable Ag for the amount of REV-ERB agonist over time. In [11], experimentalists reported that the agonist Ag decays exponentially to a negligible amount in 24 hours. Generally, a drug is considered to be negligible after 5 half-lives [33]. Therefore, we take the half-life of Ag to be 4.8 hours, so that Ag undergoes 5 half-lives in 24 hours. Then

In the REV-ERB agonist simulations, the model equations for the repression term $Rs$ and activation term $As$ in $dSdt$ are adjusted so that Ag acts like REV.

We chose a single injection of Ag to be double the REV peak value to exaggerate the effects of the agonist. This value could be adjusted as appropriate.

Note: The content above has been extracted from a research article, so it may not display correctly.

Q&A